GLP-1 Receptor Agonists: New Insights on Kidney, Joint, and Heart Health

Recent research into semaglutide (Ozempic, Wegovy) reveals benefits extending beyond weight loss, including improved kidney function, reduced joint replacement risk, and cardiovascular protection—many effects appear independent of weight reduction.

Kidney Function and Survival in Type 2 Diabetes

A new analysis of the FLOW trial indicates that weekly semaglutide injections are associated with improved kidney function and reduced risk of kidney failure and death in people with type 2 diabetes and chronic kidney disease. The analysis included patients with a history of heart attacks, strokes, or heart failure.

According to the study authors, the findings build on previous research showing consistent benefits in preventing cardiovascular events in this patient population. Chronic kidney disease affects an estimated 2.7 million Australian adults. The Therapeutic Goods Administration approved Ozempic to reduce kidney disease progression in people with type 2 diabetes and chronic kidney disease last year.

Study Parameters

The FLOW trial was funded by Novo Nordisk, the manufacturer of Ozempic and Wegovy. The Heart Foundation stated that industry sponsorship is standard for major clinical trials involving this class of medicines, and conflicts are managed through independent governance steering groups.

The study population was predominantly older, male, and white. Researchers noted they wished for longer study duration for greater statistical power on secondary outcomes. Despite these limitations, the analysis contributes evidence of semaglutide's potential benefit for high-risk populations.

Knee Osteoarthritis Outcomes

Research published in Regional Anesthesia & Pain Medicine examined the association between GLP-1 receptor agonist use and knee replacement surgery rates in patients with knee osteoarthritis. The University of Maryland School of Medicine analyzed data on 6.8 million adults diagnosed with knee osteoarthritis between 2010 and 2024.

Key Data Points

• A matched sample of 42,000 patients who had taken GLP-1 medications for at least one year was compared with an equal number of similar patients who had not.
• Data from 31,000 patients on these drugs for three years were analyzed.
• Taking GLP-1 medications for one year was associated with a 1.4-percentage-point lower risk of knee replacement at three years and a 2.8-percentage-point lower risk at eight years.
• Taking semaglutide or tirzepatide for three years was associated with a nearly 5-percentage-point lower chance of needing knee replacement at eight years.

The authors estimate that if all eligible patients with knee arthritis and obesity or metabolic disease took these drugs for three years, there could be up to 14,400 fewer knee replacements annually in the US and more than 1,500 fewer in the UK.

Expert Responses

Mark Bowditch, consultant knee surgeon and immediate past president of the British Orthopaedic Association, cautioned that the findings do not prove these drugs prevent surgery. He stated that "GLP-1 receptor agonists are not approved for the treatment of osteoarthritis, and we would strongly caution against their use for this purpose outside of clinical trials."

Prof Lucy Donaldson, director of research at Arthritis UK, stated the findings could help understand the potential impact of weight-loss medications to avoid or delay joint replacement.

Cartilage Restoration and Metabolic Mechanisms

A study published on February 9 in Cell Metabolism indicates that GLP-1 drugs may influence joint health through mechanisms separate from weight reduction. The research, titled "Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism," involved mouse experiments and a small randomized human trial.

Animal and Human Trial Results

In mice treated with semaglutide, researchers observed:

• Reduced pain and decreased cartilage degeneration
• Fewer bone spurs and less severe lesions in joint membranes
• A control group of "pair-fed" mice, which experienced comparable weight changes without semaglutide, did not show the same cartilage protection

For the human trial, 20 individuals aged 50-75 with both obesity and osteoarthritis were randomized into two groups: one received sodium hyaluronate (HA), and the other received HA plus semaglutide. After 24 weeks, the HA-plus-semaglutide group reported lower osteoarthritis pain scores and improvements in knee function. MRI analysis revealed thicker cartilage and recent cartilage growth in the inner joint areas that bear weight.

Biological Pathway

The study identified the "GLP-1R-AMPK-PFKFB3 axis" as the primary biological pathway altered by semaglutide. In osteoarthritis-affected mice, chondrocytes (cartilage cells) primarily utilized glycolysis, an oxygen-independent process producing two ATP molecules per glucose. Following semaglutide treatments, oxidative phosphorylation (OXPHOS), an oxygen-dependent process producing up to 36 ATP molecules per glucose, became the preferred metabolic pathway.

Weight Loss-Independent Effects Across Organ Systems

A separate analysis reported that the health benefits of GLP-1 drugs may not depend solely on weight loss across several conditions:

• Heart Outcomes: 66% of the reduction in major adverse cardiovascular events (MACE) was unrelated to weight loss, with arterial inflammation reducing immediately.
• Kidney Health: A 100% effect on kidney outcomes was observed to be independent of weight loss, involving direct interaction with GLP-1 receptors in the kidney.
• Liver Health: For metabolic dysfunction-associated steatohepatitis (MASH), 50-70% of the benefit was unrelated to weight loss, including reduced lipotoxicity and improved liver enzymes before any weight loss occurred.

Limitations and Context

Researchers noted that mouse study findings do not always translate to long-term human outcomes. The authors of the osteoarthritis study concluded that the protective effects on the human knee joint require further validation through clinical trials.

GLP-1 medications require a prescription and carry risks and side effects. The Heart Foundation has recommended semaglutide for weight loss in people with established cardiovascular disease to reduce future risk.

Osteoarthritis affects approximately 600 million people globally and is projected to impact one billion by 2050. The condition is also increasing among younger populations. Over 500 million people globally have osteoarthritis, with knee arthritis affecting about 14 million in the US and over 5 million in the UK. More than 120,000 knee replacements are performed annually in the UK.